Clinical trials: Medullary Thyroid Cancer (MTC), active
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Trial name
- NCT06444880
- Testing
- Ubamatamab, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas
MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas
This Phase II study will evaluate toripalimab plus axitinib in adults with previously untreated, synchronous metastatic non-clear cell renal cell carcinoma and renal medullary carcinomas whose primary kidney tumor remains in…
- Trial name
- MANTIS-RCC (NCT07816770)
- Testing
- Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy
- Volunteers
- 30 people
- Sponsor
- Fudan University
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in…
- Conditions
- Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8
- Trial name
- NCT04216732
- Testing
- Blood Pressure Measurement, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 2,030 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Cancer
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
- Trial name
- NCT05830500
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 19 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Study of SNH-118110 in Advanced Solid Tumors
This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally.
- Trial name
- SNH-118110 (NCT07649200)
- Testing
- SNH-118110 Soft Capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- ScinnoHub Pharmaceutical Co., Ltd.
Cardiovascular Disorder, Chronic Kidney Disease
Cancer and Blood Pressure Management, CARISMA Study
This phase II trial studies how well intensive blood pressure management works in decreasing systolic blood pressure in patients with kidney or thyroid cancer that has spread to other places in the body (metastatic) who are…
- Conditions
- Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT04467021
- Testing
- Best Practice, Blood Pressure Measurement, Clinical Management
- Where
- 25 sites in United States
- Volunteers
- 61 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Medullary Thyroid Carcinoma, Hyperparathyroidism
PET-TC in Thyroid Evaluation
The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies.
- Conditions
- Medullary Thyroid Carcinoma, Hyperparathyroidism, Parathyroid Carcinoma
- Trial name
- PEPATI-MN-2024 (NCT06852144)
- Testing
- clinical practice drug treatment
- Where
- Italy
- Volunteers
- 418 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Medullary Thyroid Carcinoma
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
This is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial, aims to compare 68Ga-CTR-FAPI PET-CT-guided surgery to investigator-chosen surgical approaches to evaluate its efficacy in treating newly…
- Trial name
- CAST-MTC (NCT07383246)
- Testing
- 68Ga-CTR-FAPI PET-CT guided surgery, investigator choice of surgery
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone.
- Conditions
- Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma
- Trial name
- NCT04071223
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 47 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer (MTC)
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
This trial is a prospective, observational Phase II clinical study. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly…
- Trial name
- NCT07048964
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Medullary Thyroid Carcinoma
Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid Cancer
This is a prospective multicenter observational study on medullary thyroid cancer , aiming to investigate the correlation of stromal desmoplastic reaction with tumor aggressiveness.
- Trial name
- DESMED (NCT07851324)
- Testing
- lobectomy with lymph node dissection
- Volunteers
- 74 people
- Sponsor
- Aristotle University Of Thessaloniki
Phase II, Sacituzumab
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.
- Conditions
- Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
- Trial name
- NCT07438626
- Testing
- Sacituzumab tirumotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Gland Medullary Carcinoma
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic).
- Trial name
- NCT07612293
- Testing
- Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thyroid Gland Medullary Carcinoma
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
This trial develops and studies how well a patient decision aid works in supporting decision-making about when to start or stop new drugs, join clinical trials, or continue active cancer monitoring for patients with medullary…
- Trial name
- NCT03892993
- Testing
- Decision Aid, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
This trial tests how well giving enfortumab vedotin works for the treatment of differentiated thyroid cancer that does not respond to treatment with radioiodine (refractory), anaplastic thyroid cancer, medullary thyroid cancer or…
- Conditions
- Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT07863765
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Northwestern University